Leah Fung, Ph.D.

As Vice President of Medicinal Chemistry at BioTheryX, Dr. Leah Fung is responsible for
medicinal chemistry and computational chemistry as well as BioTheryX’s PHM® library and intellectual property. Dr. Fung has over 28 years of experience as a medicinal chemist in the pharmaceutical and biotech industry. Prior to joining BioTheryX, Dr. Fung served as Vice President of Medicinal Chemistry at NovoMedix and led drug discovery research efforts to discover antifibrotic and breast cancer development candidates that are entering into IND-enabling studies. Dr. Fung was also Associate Director of Medicinal Chemistry at Structural Genomix and Assistant Director of Medicinal Chemistry at Structural Bioinformatics, leading multi-disciplinary research teams at both companies to discover tyrosine kinase protein inhibitors as novel cancer therapeutics using fragment-based approaches for lead discovery as well as crystallography and computational methods for lead optimization. Dr. Fung has also held leadership positions at Celgene, Signal Pharmaceuticals, and Houghten Pharmaceuticals. While at Celgene and Signal, Dr. Fung successfully optimized screening hits into development candidates for non-cancer and cancer indications, including a selective estrogen reception modulator (SERM), which in collaboration with Novartis, advanced into clinical studies for estrogen receptor-positive breast cancer. Also, Dr. Fung was among leading scientists who pioneered high-throughput parallel synthesis technologies and combinatorial chemistries and has authored or co-authored over 20 peer-reviewed publications. Additionally, Dr. Fung is co-inventor on more than 30 issued US patents and hundreds of international patents. Dr. Fung received her Ph.D. in Organic Chemistry from the University of California, Irvine.